A phase II trial of LMI-1195 for use in cardiac PET to assess myocardial presynaptic sympathetic nerve function

Trial Profile

A phase II trial of LMI-1195 for use in cardiac PET to assess myocardial presynaptic sympathetic nerve function

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Mar 2018

At a glance

  • Drugs LMI 1195 (Primary)
  • Indications Heart failure; Ischaemic heart disorders
  • Focus Diagnostic use
  • Most Recent Events

    • 15 Mar 2018 New trial record
    • 12 Mar 2018 Data from this trial will be presented at the American College of Cardiology's 67th Annual Scientific Session (ACC.18), according to a Lantheus Medical Imaging media release.
    • 12 Mar 2018 Results presented in a Lantheus Medical Imaging media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top